Antibody "cocktail" therapy for COVID-19 inpatients: positive clinical data have been obtained

Regeneron today announced encouraging preliminary data from the ongoing Phase I/II/III clinical trial of the Regeneron antibody "cocktail" (casirivimab and imdevimab) for the treatment of COVID-19 hospitalized patients.
study aims to focus on patients who have not yet developed an autoimmune response to SARS-CoV-2 (i.e., no antibodies at baseline, serum negative) because previous evidence suggests that these patients are at higher risk.
analysis, antibody "cocktail" therapy can reduce the risk of death or mechanical aeration by about half.
In serum-negative patients, the antibody "cocktail" reduced the daily viral load by -0.54 log10 copies/mL on the 7th day and by -0.63 log10 copies/mL on the 11th day (p -0.002).
patients have good tolerance to antibody "cocktail" therapy.
in the entire trial population, the rate of high-dose severe adverse events was 21%, the rate of low-dose serious adverse events was 20%, and the placebo was 24%. infusion reactions from
high-dose antibody mixtures (2.7% high-dose, 0.9% low-dose, 1.4% placebo) were more common, and infusion-related reactions resulted in two treatment interruptions, both in the high-dose group.
。